SUVENNSESuven Life Sciences Limited· PharmaceuticalsMediumNeutral
Announced Fri, 22 Aug · 15:58 IST

Suven Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 22, 2025

Board & Shareholder Meetings View source PDF

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Suven Life Sciences held its 36th Annual General Meeting on August 22, 2025, via video conferencing, attended by 60 members. All three ordinary resolutions were passed with overwhelming majority: adoption of audited financial statements for FY ending March 31, 2025 (99.999% in favour), re-appointment of Smt. Sudharani Jasti as director (99.996% in favour), and appointment of Secretarial Auditors (99.999% in favour). The Chairman informed members that both the Auditors' Report and Secretarial Audit Report contained no qualifications or adverse remarks. Remote e-voting ran from August 18-21, 2025, with e-voting during the AGM facilitated by KFin Technologies. The Scrutinizer, D. Renuka, confirmed all resolutions secured the requisite majority.

Likely market impact

Routine procedural filing — all resolutions passed with near-unanimous shareholder approval, indicating no governance concerns. The clean audit reports and smooth AGM conduct are positive but neutral signals for shareholders, with no material business impact on the stock price.